4/4/2011

Watson Pharmaceuticals obtained FDA approval to market a generic version of Ferrlecit, Sanofi-Aventis' injectable treatment for iron-deficiency anemia in patients age 6 and older. Watson will market its product as Nulecit.

Full Story:
Drug Store News

Related Summaries